Abstract Library

#3273 LIBRETTO-531: Selpercatinib vs standard of care in patients (pts) with multikinase inhibitor-naïve advanced or metastatic RET-mutant (mut) medullary thyroid cancer (MTC)

Introduction: Multikinase inhibitors (MKI) are approved for MTC; however, their efficacy in RETmut MTC is limited due to incomplete RET inhibition and significant toxicity. Selpercatinib (LOXO-292), a highly selective and potent FDA approved inhibitor of RET alterations including M918T, MKI resistance-associated V804M, and others, showed robust, durable clinical activity with a tolerable profile in pts with RETmut MTC in the Phase 1/2 LIBRETTO-001 study.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Leboulleux S, Robinson B, Hoff A, Brose M, Wirth L,

Keywords: RET alteration, medullary thyroid cancer (MTC), phase 3 trial, selpercatinib,

#831 Overall Survival (OS) as a Function of the Number of Therapeutic Lines in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDpNET)

Introduction: At least 9 therapeutic options are now available for unresectable WDpNET patients. Whether all lines can be administrated before tumor or toxic-related deaths is currently unknown.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Berdelou A, Malka D, Leboulleux S, Boige V, Chougnet C,

Keywords: pNets,

#507 Are all Metastatic Grade 3 WHO 2010 Neuroendocrine Carcinoma Poorly Differentiated?

Introduction: The WHO classification 2010 for neuroendocrine tumors (NET) defines poorly differentiated neuroendocrine carcinomas (NEC) as grade 3 (G3) according to mitoses> 20/10 HPF and/or Ki-67>20%.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Vélayoudom-Céphise F, Duvillard P, Malka D, Leboulleux S, Guigay J,

Keywords: proliferation index, neuroendocrine tumors,

#320 Predictors of Clinical Response to Everolimus in Patients with Well-differentiated Metastatic Pancreatic NETs

Introduction: Everolimus (E) is an mTOR inhibitor with promising antitumor activity in patients with NETs. Predictor factors of response could improve the clinical use of this compound.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: De Martino M, Ducreux M, Dromain C, Duvillard P, Guigay J, Leboulleux S,

Keywords: everolimus, mTOR, RECIST, pancreas, neuroendocrine, tumor, proliferative index, predictor,

#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors

Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Fekih M, Baudin E, Ducreux M, Chougnet C, Leboulleux S,

Keywords: carcinoid tumor, neuroendocrine tumors, therapeutics, Somatostatin analogues, lung,